Iodine-131—Metaiodobenzylguanidine Double Infusion With Autologous Stem-Cell Rescue for Neuroblastoma: A New Approaches to Neuroblastoma Therapy Phase I Study

Matthay, Katherine K.; Quach, Alekist; Huberty, John P.; Franc, Benjamin L.; Hawkins, Randall A.; Jackson, Hollie A.; Groshen, Susan; Shusterman, Suzanne; Yanik, Gregory A.; Veatch, Janet; Brophy, Patricia; Villablanca, Judith G.; Maris, John M.

doi:10.1200/jco.2007.15.7628

Cited by 110 publications

(76 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…177 Lu-DOTATATE offers a unique treatment target and differs from 131 I-MIBG and chemotherapy in its mode of action. We recognize the success of 131 I-MIBG therapy (26)(27)(28)(29) and do not propose 177 Lu-DOTATATE as a competitor but as a therapeutic option for those who have relapsed or have primary refractory disease and who may or may not have already received 131 I-MIBG therapy. A combination of the 2 agents may be more effective than either used alone.…”

Section: Discussionmentioning

confidence: 99%

¹⁷⁷Lu-DOTATATE Molecular Radiotherapy for Childhood Neuroblastoma

Gains¹,

Bomanji²,

Fersht³

et al. 2011

J Nucl Med

148

141

View full text Add to dashboard Cite

This study tested the principle that 68 Ga-DOTATATE PET/CT may be used to select children with primary refractory or relapsed high-risk neuroblastoma for treatment with 177 Lu-DOTATATE and evaluated whether this is a viable therapeutic option for those children. Methods: Between 2008 and 2010, 8 children with relapsed or refractory high-risk neuroblastoma were studied with 68 Ga-DOTATATE PET/CT. The criterion of eligibility for 177 Lu-DOTATATE therapy was uptake on the diagnostic scan equal to or higher than that of the liver. Results: Of the 8 children imaged, 6 had abnormally high uptake on the 68 Ga-DOTATATE PET/CT scan and proceeded to treatment. Patients received 2 or 3 administrations of 177 Lu-DOTATATE at a median interval of 9 wk and a median administered activity of 7.3 GBq. Of the 6 children treated, 5 had stable disease by the response evaluation criteria in solid tumors (RECIST). Of these 5 children, 2 had an initial metabolic response and reduction in the size of their lesions, and 1 patient had a persistent partial metabolic response and reduction in size of the lesions on CT, although the disease was stable by RECIST. One had progressive disease. Three children had grade 3 and 1 child had grade 4 thrombocytopenia. No significant renal toxicity has been seen. Conclusion: 68 Ga-DOTATATE can be used to image children with neuroblastoma and identify those suitable for molecular radiotherapy with 177 Lu-DOTATATE. We have shown, for what is to our knowledge the first time, that treatment with 177 Lu-DOTATATE is safe and feasible in children with relapsed or primary refractory high-risk neuroblastoma. We plan to evaluate this approach formally in a phase I-II clinical trial.

show abstract

Section: Discussionmentioning

confidence: 99%

¹⁷⁷Lu-DOTATATE Molecular Radiotherapy for Childhood Neuroblastoma

Gains¹,

Bomanji²,

Fersht³

et al. 2011

J Nucl Med

148

141

View full text Add to dashboard Cite

show abstract

“…This point is evident in our current and prior reports on salvage chemotherapy for NB [8][9][10][11] as well as in experience with 131 I-MIBG therapy. 39 PBSC support also has allowed the investigation of novel submyeloablative induction chemotherapy regimens against NB 37,40 and other solid tumors in children. 36,41 We conclude that, in patients with high-risk NB, turning to HD-ICE for salvage or consolidative therapy is an attractive option because of noncross-resistance with widely used retrieval regimens.…”

Section: Discussionmentioning

confidence: 99%

Ifosfamide, carboplatin, and etoposide for neuroblastoma

Kushner

Modak

Krämer

et al. 2012

Cancer

View full text Add to dashboard Cite

BACKGROUND:The authors report a retrospective analysis of high-dose ifosfamide, carboplatin, and etoposide (HD-ICE) for patients with refractory or relapsed neuroblastoma (NB). A major reason for using this regimen was the long time since patients received previous treatment with a platinum compound. The authors also summarized the published experience on ICE in patients with NB. METHODS: Treatment comprised ifosfamide (2000 mg/m 2 daily for 5 days), carboplatin (500 mg/m 2 daily for 2 days), and etoposide (100 mg/m 2 daily for 5 days). Patients who had poor hematologic reserve (platelet count <100,000/lL) from previous therapy received peripheral blood stem cells (PBSCs) after HD-ICE. Disease status before and after HD-ICE was defined according to International Neuroblastoma Response Criteria (expanded to include 123 I-metaiodobenzylguanidine findings). Publications that were informative about ICE for NB were reviewed. RESULTS: Seventy-four patients received 92 cycles of ICE, including 37 patients who received PBSC rescue. Grade 3 toxicities were rare: 1-3 patients had encephalopathy, mucositis, or gastroenteritis. Bacteremia was documented in 24 of 92 cycles (26%). The absolute neutrophil count reached 500/lL on day 17-30 (median, day 22) in patients who had satisfactory hematologic reserve. Disease regressions (major and minor responses) were achieved by 14 of 17 patients (82%) with a new relapse, 13 of 26 patients (50%) with refractory NB, and 12 of 34 patients (35%) who were treated for progressive disease during chemotherapy (P ¼ .005). In the literature, patients received ICE at lower dosages and achieved major response rates >36% in phase 1 and 2 studies (in which less comprehensive staging evaluations were used) that involved resistant NB and >70% in induction for newly diagnosed NB. CONCLUSIONS: HD-ICE is appealing as salvage treatment or consolidative therapy because of its anti-NB activity and the low risk of major nonhematologic toxicity. PBSC support is unnecessary for patients who had intact hematologic reserve.

show abstract

“…Increasing tumor radiation dose: the response rate of 42 mCi/kg dose did not appear to be different from that obtained with the standard 18 mCi/kg dose [31].…”

Section: Targeting Human Norepinephrine Transporter (Hnet) With 131 Imentioning

confidence: 96%

Target Therapy in Neuroblastoma

Hassan¹,

Badr²,

Safy³

et al. 2017

Neuroblastoma - Current State and Recent Updates

View full text Add to dashboard Cite

Neuroblastoma is an embryonal malignancy that originates in the sympathetic nervous system. It is the most common solid tumor in infants and the most frequent extracranial solid tumor in children. Neuroblastoma accounts for 10% of childhood malignancies with 75% occurring in children <4 years. Stage, age, clinical and tumor genomic features are the principal criteria for determining treatment policy. Treatment modalities traditionally employed in the management of neuroblastoma are surgery, chemotherapy, and radiotherapy. Intensive multimodal treatment in patients with neuroblastoma has resulted in improved survival rates. However, there is a considerable percentage of patients with refractory and relapsed disease. Targeted therapy for neuroblastoma involves treatment aimed at molecular targets that have a unique expression in this childhood cancer. A large number of molecular targets have been identified for the treatment of high-risk and relapsed neuroblastoma. Treatment in this way aims at providing a more selective way to treat the disease and decreasing toxicities associated with the conventional treatment regimen.

show abstract

Iodine-131—Metaiodobenzylguanidine Double Infusion With Autologous Stem-Cell Rescue for Neuroblastoma: A New Approaches to Neuroblastoma Therapy Phase I Study

Cited by 110 publications

References 22 publications

¹⁷⁷Lu-DOTATATE Molecular Radiotherapy for Childhood Neuroblastoma

¹⁷⁷Lu-DOTATATE Molecular Radiotherapy for Childhood Neuroblastoma

Ifosfamide, carboplatin, and etoposide for neuroblastoma

Target Therapy in Neuroblastoma

Contact Info

Product

Resources

About

Iodine-131—Metaiodobenzylguanidine Double Infusion With Autologous Stem-Cell Rescue for Neuroblastoma: A New Approaches to Neuroblastoma Therapy Phase I Study

Cited by 110 publications

References 22 publications

177Lu-DOTATATE Molecular Radiotherapy for Childhood Neuroblastoma

177Lu-DOTATATE Molecular Radiotherapy for Childhood Neuroblastoma

Ifosfamide, carboplatin, and etoposide for neuroblastoma

Target Therapy in Neuroblastoma

Contact Info

Product

Resources

About

¹⁷⁷Lu-DOTATATE Molecular Radiotherapy for Childhood Neuroblastoma

¹⁷⁷Lu-DOTATATE Molecular Radiotherapy for Childhood Neuroblastoma